Table 3.
Influence of different factors in reinfection rates. Reinfection after SVR12 during follow-up according to harm reduction programs, comorbidities, and drug use
| Follow-up | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months | 12 months | 24 months | 3 years | ||||||
| N (%) | Reinfected n (%) |
N (%) | Reinfected n (%) |
N (%) | Reinfected n (%) |
N (%) | Reinfected n (%) |
||
| Harm reduction programs2 |
Yes n (%) |
58 (100.0) |
0 (0.0) | 58 (100.0) | 1 (1.7) | 47 (100.0) | 1 (2.1) | 31 (100.0) | 1 (3.2) |
|
No n (%) |
75 (100.0) |
1 (1.3) | 73 (100.0) | 0 (0.0) | 76 (100.0) | 1 (1.3) | 71 (100.0) | 0 (0.0) | |
| P1 | 1.000 | 0.443 | 1.000 | 0.304 | |||||
| HIV-HCV3 |
Yes n (%) |
69 (100.0) | 1 (1.4) | 76 (100.0) | 0 (0.0) | 75 (100.0) | 1 (1.3) | 61 (100.0) | 0 (0.0) |
|
No n (%) |
73 (100.0) | 0 (0.0) | 64 (100.0) | 1 (1.6) | 62 (100.0) | 1 (1.6) | 53 (100.0) | 1 (1.9) | |
| P1 | 0.486 | 0.457 | 1.000 | 0.465 | |||||
| Psychiatric illness3 |
Yes n (%) |
52 (100.0) | 1 (1.9) | 51 (100.0) | 0 (0.0) | 43 (100.0) | 1 (2.3) | 30 (100.0) | 0 (0.0) |
|
No n (%) |
90 (100.0) | 0 (0.0) |
89 (100.0) |
1 (1.1) | 94 (100.0) | 1 (1.1) | 84 (100.0) | 1 (1.2) | |
| P1 | 0.366 | 1.000 | 0.531 | 1.000 | |||||
| People who use drugs actively2 |
Yes n (%) |
53 (100.0) | 0 (0.0) | 53 (100.0) | 1 (1.9) | 45 (100.0) | 2 (4.4) | 36 (100.0) | 1 (2.8) |
|
No n (%) |
84 (100.0) | 1 (1.2) | 81 (100.0) | 0 (0.0) | 85 (100.0) | 0 (0.0) | 69 (100.0) | 0 (0.0) | |
| P1 | 1.000 | 0.396 | 0.118 | 0.343 | |||||
| People who inject drugs |
Yes n (%) |
6 (100.0) | 0 (0.0) | 8 (100.0) | 1 (12.5) | 8 (100.0) | 1 (12.5) | 5 (100.0) | 0 (0.0) |
|
No n (%) |
47 (100.0) | 0 (0.0) | 45 (100.0) | 0 (0.0) | 36 (100.0) | 0 (0.0) | 31 (100.0) | 1 (3.2) | |
| P1 | - | 0.151 | 0.182 | 1.000 | |||||
n = 2 reinfected patients described at additional visit have been considered within 2-years follow-up, because they have occurred at 15.9 and 28.3 months
1Fisher’s exact test
2At reinfection time
3At baseline